- Home
- OGI vs PBYI Comparison
OGI vs PBYI Comparison
Compare OGI & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OGI
- PBYI
- Stock Information
- Founded
- OGI 2013
- PBYI 2010
- Country
- OGI Canada
- PBYI United States
- Employees
- OGI N/A
- PBYI N/A
- Industry
- OGI Biotechnology: Pharmaceutical Preparations
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- OGI Health Care
- PBYI Health Care
- Exchange
- OGI Nasdaq
- PBYI Nasdaq
- Market Cap
- OGI 176.1M
- PBYI 176.1M
- IPO Year
- OGI N/A
- PBYI N/A
- Fundamental
- Price
- OGI $1.84
- PBYI $2.56
- Analyst Decision
- OGI
- PBYI Strong Buy
- Analyst Count
- OGI 0
- PBYI 1
- Target Price
- OGI N/A
- PBYI $7.00
- AVG Volume (30 Days)
- OGI 374.9K
- PBYI 338.9K
- Earning Date
- OGI 08-13-2024
- PBYI 10-31-2024
- Dividend Yield
- OGI N/A
- PBYI N/A
- EPS Growth
- OGI N/A
- PBYI N/A
- EPS
- OGI N/A
- PBYI 0.18
- Revenue
- OGI $110,297,722.00
- PBYI $219,143,000.00
- Revenue This Year
- OGI $8.76
- PBYI N/A
- Revenue Next Year
- OGI $14.04
- PBYI N/A
- P/E Ratio
- OGI N/A
- PBYI $14.09
- Revenue Growth
- OGI 2.33
- PBYI N/A
- 52 Week Low
- OGI $0.97
- PBYI $2.13
- 52 Week High
- OGI $2.91
- PBYI $7.73
- Technical
- Relative Strength Index (RSI)
- OGI 51.18
- PBYI 45.60
- Support Level
- OGI $1.76
- PBYI $2.48
- Resistance Level
- OGI $2.00
- PBYI $2.64
- Average True Range (ATR)
- OGI 0.09
- PBYI 0.14
- MACD
- OGI -0.01
- PBYI 0.06
- Stochastic Oscillator
- OGI 42.86
- PBYI 80.49
About OGI Organigram Holdings Inc.
OrganiGram Holdings Inc is engaged in producing indoor-grown cannabis for patients and adult recreational consumers in Canada. The company has also developed a portfolio of adult-use recreational cannabis brands including Edison, Big Bag o' Buds, SHRED, Monjour, Holy Mountain, and Trailblazer. Tremblant Cannabis, and artisanal craft brand, Laurentian are recent additions to Organigram's existing brand portfolio.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.